Photodynamic therapy of vulvar lichen sclerosus with 5-aminolevulinic acid.

OBJECTIVE To evaluate the therapeutic effect of photodynamic therapy on vulvar lichen sclerosus. METHODS Twelve women with lichen sclerosus were enrolled in a prospective, single-arm pilot study. Four to 5 hours before photodynamic therapy, 10 mL of a 20% solution of 5-aminolevulinic acid was applied topically to the vulva. Photodynamic therapy was administered with an irradiation of 80 J/cm2 at an irradiance of 40-70 mW/cm2. Light with a wavelength of 635 nm was delivered by an argon ion-pumped dye laser. The degree of pruritus was evaluated using a horizontal visual analog scale before and after 6-8 weeks, and patients were followed tri-monthly after photodynamic therapy. RESULTS Two women underwent two cycles of photodynamic therapy, one underwent three cycles, and the remaining nine women underwent one cycle each. Treatment was tolerated moderately well, with eight patients not requiring any analgesia; three treated with opioids intravenously during the procedure, due to burning sensations; and one undergoing separation of adhesions under general anesthesia. Minimal local toxicity included vulvar erythema but no necrosis, sloughing, or scarring. No generalized cutaneous photosensitivity was present. Six to 8 weeks after photodynamic therapy, pruritus significantly improved in ten of the 12 women. A prolonged effect of photodynamic therapy was reported, with a mean of 6.1 months. CONCLUSION Photodynamic therapy after topical application of 5-aminolevulinic acid produced statistically significant relief of symptoms of vulvar lichen sclerosus for an average of 6.1 months with minimal side effects.

[1]  P. Speight,et al.  Photodynamic therapy using 5‐aminolevulinic acid for premalignant and malignant lesions of the oral cavity , 1996, Cancer.

[2]  T J Dougherty,et al.  Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. , 1976, Cancer research.

[3]  E. Wilkinson Benign Diseases of the Vulva , 1994 .

[4]  K. Dalziel,et al.  The treatment of vulval lichen sclerosus with a very potent topical steroid (clobetasol Propionate 0.05%) cream , 1991, The British journal of dermatology.

[5]  E. L. Powers,et al.  Oxygen and oxy-radicals in chemistry and biology , 1981 .

[6]  J C Kennedy,et al.  Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. , 1992, Journal of photochemistry and photobiology. B, Biology.

[7]  K. Nakanishi,et al.  A NON‐TYPICAL CYCLOBUTANE DIMER PHOTOPROD ‡ FROM 5‐ETHYLOROTATE , 1984 .

[8]  M. Sideri,et al.  Topical testosterone in the treatment of vulvar lichen sclerosus , 1994, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[9]  A Gorchein,et al.  Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study. , 1995, Gut.

[10]  G. Gitsch,et al.  Short-Term Effects of Topical Testosterone in Vulvar Lichen Sclerosus , 1997 .

[11]  P. Carli,et al.  Testosterone maintenance therapy. Effects on vulvar lichen sclerosus treated with clobetasol propionate. , 1996, The Journal of reproductive medicine.

[12]  M. Ochsner Photophysical and photobiological processes in the photodynamic therapy of tumours. , 1997, Journal of photochemistry and photobiology. B, Biology.

[13]  K. Dalziel,et al.  Long-term control of vulval lichen sclerosus after treatment with a potent topical steroid cream. , 1993, The Journal of reproductive medicine.

[14]  P. Carli,et al.  Clinical and histologic effects of topical treatments of vulval lichen sclerosus. A critical evaluation. , 1993, The Journal of reproductive medicine.